GLP-1 and Smoking Cessation: Can It Help You Quit?

Introduction

The same brain circuits that semaglutide quiets for food and alcohol cravings overlap with nicotine reward pathways. So when patients started reporting they’d quit smoking on GLP-1 drugs without really trying, researchers paid attention. The early evidence is preliminary but consistent enough to take seriously.

A 2024 retrospective analysis from Wang and colleagues in Annals of Internal Medicine looked at over 220,000 patients with type 2 diabetes and tobacco use disorder. Those prescribed semaglutide had a 32% lower rate of nicotine-related medical encounters over a year compared with patients on other diabetes drugs. The signal was strongest in patients who weren’t actively trying to quit.

Whether semaglutide or tirzepatide will end up FDA-approved for smoking cessation is unclear. But the pharmacology and the early data suggest a real effect.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

How Might Semaglutide Help with Quitting Smoking?

Through the same reward-pathway mechanism that affects food and alcohol cravings. GLP-1 receptors are present in the ventral tegmental area and nucleus accumbens, the brain regions where nicotine produces its dopamine reward. Rodent studies going back to 2013 by Egecioglu and colleagues showed GLP-1 agonists reduced nicotine self-administration and nicotine-induced dopamine release.

Quick Answer: A 2024 Annals of Internal Medicine analysis by Wang et al. of 220,000+ patients showed semaglutide users had a 32% lower rate of nicotine-related medical encounters over a year

In humans, the mechanism seems similar. Patients describe cigarettes losing their appeal, becoming less satisfying, or just being forgotten. The pull isn’t there. This is the same language patients use for alcohol on GLP-1 drugs.

There’s a second mechanism specific to smoking. People often resist quitting because of fear of weight gain, which averages 5-15 pounds in the year after cessation. GLP-1 drugs eliminate this concern, removing a real psychological barrier.

What Does the Smoking Cessation Trial Data Actually Show?

The most rigorous data comes from a 2025 phase 2 trial by Yammine and colleagues testing exenatide (a shorter-acting GLP-1) for smoking cessation in 84 adults. Over 6 weeks of treatment, the exenatide group had slightly fewer cigarettes per day and somewhat lower cravings, but the difference didn’t reach statistical significance on the primary outcome.

The trial was small and short. Critics noted that the GLP-1 used was exenatide rather than the more potent semaglutide or tirzepatide, and the dose was modest. Larger trials with semaglutide are running.

The retrospective database studies show more striking effects. Beyond the 2024 Wang et al. analysis, a 2024 paper in Nicotine & Tobacco Research found semaglutide users had higher quit rates over a year than matched controls, with hazard ratios suggesting roughly 1.5x higher likelihood of sustained abstinence.

Will GLP-1 Prevent Post-cessation Weight Gain?

Almost certainly yes, and this is probably one of the most useful applications for patients who need to quit. Average weight gain after quitting smoking is 5-15 pounds in the first year, with about 13% of quitters gaining more than 22 pounds. This weight gain is one of the most common reasons people relapse to smoking, especially women.

GLP-1 drugs produce active weight loss while the patient is quitting. The pharmacology directly counters the metabolic and behavioral changes that drive post-cessation weight gain. Patients quitting on semaglutide or tirzepatide typically continue losing weight rather than gaining.

This is a meaningful advantage. For patients who’ve failed previous quit attempts because of weight concerns, GLP-1 treatment may shift the cost-benefit calculation enough to make cessation possible.

How Does GLP-1 Compare with Varenicline or Bupropion for Quitting?

The current FDA-approved smoking cessation drugs are varenicline (Chantix), bupropion (Zyban), and nicotine replacement therapy. Varenicline is the most effective, with quit rates roughly 2-3x higher than placebo at 12 months.

GLP-1 drugs haven’t been tested head-to-head against varenicline. The retrospective data suggests semaglutide effects are smaller than varenicline’s but the comparison isn’t clean. Both drug classes affect dopamine reward, but varenicline is specifically designed for nicotine receptors while semaglutide is broader.

For patients who already need a GLP-1 for weight or diabetes, adding smoking cessation as a secondary benefit makes sense. For patients only wanting help with quitting, varenicline remains the first-line pharmacological option.

Can You Take Semaglutide Together with Varenicline?

Yes, in most cases. There are no major pharmacokinetic interactions between the two drug classes. Some prescribers stack them, particularly in patients with both obesity and tobacco use disorder.

The combined regimen targets nicotine reward through two different mechanisms (varenicline at acetylcholine receptors, semaglutide at GLP-1 receptors in reward circuits) and also addresses the weight gain barrier. No controlled trial has tested this combination, but case reports and clinic experience are favorable.

Watch for nausea, which is common to both drugs. Stack titration if both are being started, or stagger the introduction by a few weeks.

Key Takeaway: Most patients on GLP-1 don’t gain the typical 5-15 pounds associated with quitting smoking, removing a major barrier to cessation

What If I’m Not Actively Trying to Quit Smoking?

This is where the retrospective data is most interesting. The Wang et al. 2024 analysis found that the GLP-1 effect on smoking outcomes was largest in patients who hadn’t been recorded as actively trying to quit. The drug seems to reduce nicotine cravings independent of intention to stop.

Many patient reports describe a similar pattern. They started semaglutide for weight loss, gradually noticed they were smoking less, and eventually quit without making it a goal. This is similar to the alcohol pattern, where reduced cravings precede and produce behavior change rather than the other way around.

This doesn’t mean you can passively expect semaglutide to make you quit. The effect is modest in most patients. But for people who’ve thought about quitting and never quite gotten there, GLP-1 treatment may make the next attempt easier.

Does This Work for Vaping and Other Nicotine Products?

The trial and database evidence has mostly focused on cigarette smoking. Vaping and other nicotine delivery is understudied. In principle, the mechanism should generalize because the brain doesn’t care how nicotine arrives.

Patient reports suggest similar effects on vaping as on smoking, though the data is anecdotal. Some patients describe reduced interest in vaping concurrent with reduced food and alcohol cravings, all on the same GLP-1 treatment.

What Are the Risks of Using GLP-1 to Support Quitting Smoking?

The general risks of semaglutide and tirzepatide apply, including GI side effects, the rare risk of pancreatitis and gallbladder disease, and the boxed warning for medullary thyroid cancer in people with relevant family history.

There’s a specific quitting-related risk. Patients who quit smoking on GLP-1 may experience a brief period of intense food cravings as the nicotine appetite suppression goes away. The GLP-1 usually offsets this, but for a few weeks the combined effects can be uncomfortable.

Watch for mood changes too. Nicotine withdrawal includes irritability and depressed mood, and major life stressors can make this worse. GLP-1 drugs are generally mood-neutral, but quitting smoking is hard regardless of pharmacological support.

Bottom line: No GLP-1 drug is FDA-approved for smoking cessation, but the evidence is enough that some prescribers consider it off-label

FAQ

Will My Doctor Prescribe Semaglutide Just to Help Me Quit Smoking?

Probably not, unless you also have obesity or diabetes. GLP-1 drugs aren’t FDA-approved for smoking cessation and most insurance won’t cover them for that indication. Varenicline is the appropriate first-line pharmacological treatment for quitting.

What If I Have Both Obesity and Smoke?

You’re an ideal candidate for GLP-1 treatment. Both conditions improve on semaglutide or tirzepatide. The TrimRx assessment quiz covers tobacco use as part of medical history.

How Long Does It Take to Notice Reduced Nicotine Cravings on GLP-1?

Most patient reports describe noticeable changes within the first 4-8 weeks of treatment, often concurrent with reduced food and alcohol cravings. The effect tends to strengthen as the dose titrates up.

Can I Stop Semaglutide Once I’ve Quit Smoking?

You can, but expect that nicotine cravings may return along with appetite and weight. If you’re using the drug primarily for smoking support, talk to your prescriber about whether continued treatment makes sense.

Does Tirzepatide Work as Well as Semaglutide for Nicotine Cravings?

The data is thinner for tirzepatide on nicotine specifically, but the broader pharmacological profile suggests similar or potentially stronger effects. Tirzepatide produces more dramatic weight loss and stronger reward-pathway effects in general.

Will GLP-1 Help with Cannabis or Other Substance Cravings?

Limited data so far. Some animal studies and patient reports suggest broader effects on reward-driven behaviors, including cannabis use. Controlled trials are ongoing but no firm conclusions yet.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.